This state-of-the-art presentation focuses on recently reported data regarding the first-line management of chronic myeloid leukemia (CML) with second generation tyrosine kinase inhibitors (TKIs). Dr Hagop Kantarjian addresses these important data and provides perspectives concerning the impact on patient care and outcomes.
Features of this Educational Activity Include
- Animated illustrations
- Commentary from clinical experts
- A downloadable comprehensive slide deck
Topics
- Current standards for the management of newly diagnosed CML
- Efficacy results reported from the large randomized ENESTnd phase III clinical trial comparing imatinib with nilotinib in the first-line setting
- Comparison of tolerability associated with imatinib and nilotinib observed in the ENESTnd study
- Overview and outcome of recently reported single-arm studies evaluating second generation TKIs for the treatment of newly diagnosed CML
- Summary and expert perspectives regarding the potential impact on patient outcomes of second generation TKIs used as initial therapy
Target Audience
This educational activity has been developed to provide hematology and oncology specialists based outside of the United States with a comprehensive overview of the recent advances in the treatment of hematologic malignancies.
Presenter
Hagop Kantarjian, MD
M. D. Anderson Cancer Center
Houston, Texas
This activity is supported by
Novartis Oncology.
